JP2013519675A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013519675A5 JP2013519675A5 JP2012552978A JP2012552978A JP2013519675A5 JP 2013519675 A5 JP2013519675 A5 JP 2013519675A5 JP 2012552978 A JP2012552978 A JP 2012552978A JP 2012552978 A JP2012552978 A JP 2012552978A JP 2013519675 A5 JP2013519675 A5 JP 2013519675A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- disease
- related disorder
- pharmaceutical composition
- cns
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000010425 asbestos Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000034737 hemoglobinopathy Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 229910052895 riebeckite Inorganic materials 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30361810P | 2010-02-11 | 2010-02-11 | |
| US61/303,618 | 2010-02-11 | ||
| PCT/US2011/024269 WO2011100380A1 (en) | 2010-02-11 | 2011-02-10 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016004951A Division JP6215976B2 (ja) | 2010-02-11 | 2016-01-14 | アリールメトキシイソインドリン誘導体、それを含む組成物、及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013519675A JP2013519675A (ja) | 2013-05-30 |
| JP2013519675A5 true JP2013519675A5 (enExample) | 2014-03-27 |
Family
ID=43708752
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012552978A Withdrawn JP2013519675A (ja) | 2010-02-11 | 2011-02-10 | アリールメトキシイソインドリン誘導体、それを含む組成物、及びその使用方法 |
| JP2016004951A Active JP6215976B2 (ja) | 2010-02-11 | 2016-01-14 | アリールメトキシイソインドリン誘導体、それを含む組成物、及びその使用方法 |
| JP2016080097A Withdrawn JP2016172746A (ja) | 2010-02-11 | 2016-04-13 | アリールメトキシイソインドリン誘導体、それを含む組成物、及びその使用方法 |
| JP2016171451A Active JP6270944B2 (ja) | 2010-02-11 | 2016-09-02 | アリールメトキシイソインドリン誘導体、それを含む組成物、及びその使用方法 |
| JP2017125219A Pending JP2017200944A (ja) | 2010-02-11 | 2017-06-27 | アリールメトキシイソインドリン誘導体、それを含む組成物、及びその使用方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016004951A Active JP6215976B2 (ja) | 2010-02-11 | 2016-01-14 | アリールメトキシイソインドリン誘導体、それを含む組成物、及びその使用方法 |
| JP2016080097A Withdrawn JP2016172746A (ja) | 2010-02-11 | 2016-04-13 | アリールメトキシイソインドリン誘導体、それを含む組成物、及びその使用方法 |
| JP2016171451A Active JP6270944B2 (ja) | 2010-02-11 | 2016-09-02 | アリールメトキシイソインドリン誘導体、それを含む組成物、及びその使用方法 |
| JP2017125219A Pending JP2017200944A (ja) | 2010-02-11 | 2017-06-27 | アリールメトキシイソインドリン誘導体、それを含む組成物、及びその使用方法 |
Country Status (33)
Families Citing this family (172)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120134969A1 (en) | 2009-05-25 | 2012-05-31 | Hiroshi Handa | Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells |
| SG183257A1 (en) * | 2010-02-11 | 2012-09-27 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| EP2699091B1 (en) * | 2011-03-28 | 2017-06-21 | DeuteRx, LLC | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| WO2012149299A2 (en) | 2011-04-29 | 2012-11-01 | Celgene Corporaiton | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| ES2872967T3 (es) | 2012-06-29 | 2021-11-03 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS) |
| LT2882737T (lt) * | 2012-08-09 | 2019-04-25 | Celgene Corporation | (s)-3-(4-((4-morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-diono hidrochlorido kieta forma |
| US20140343058A1 (en) * | 2012-08-09 | 2014-11-20 | Celgene Corporation | Treatment of systemic lupus erythematosus |
| US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
| KR20210073616A (ko) * | 2012-08-09 | 2021-06-18 | 셀진 코포레이션 | 면역-관련 및 염증성 질환의 치료 |
| UA116544C2 (uk) * | 2012-08-09 | 2018-04-10 | Селджин Корпорейшн | Спосіб лікування раку з використанням 3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
| HK1211577A1 (en) * | 2012-08-09 | 2016-05-27 | 细胞基因公司 | Processes for the preparation of (s)-3-4- ((4-(morpholinomethyl) benzyl)oxy)-1-oxoisoindolin-2-yl) piperidine-2,6-dione and pharmaceutically acceptable forms thereof |
| US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
| CN104797256A (zh) | 2012-09-10 | 2015-07-22 | 细胞基因公司 | 用于治疗局部晚期乳腺癌的方法 |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| AU2014205043B2 (en) | 2013-01-14 | 2018-10-04 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| US9695145B2 (en) | 2013-01-22 | 2017-07-04 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| AU2014236597A1 (en) | 2013-03-14 | 2015-09-24 | Deuterx, Llc | 3-(substituted-4-oxo-quinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| EP2970372B1 (en) | 2013-03-15 | 2020-09-30 | Celgene Corporation | Modified t lymphocytes |
| CA2908954C (en) | 2013-04-17 | 2021-08-03 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer |
| UA117141C2 (uk) * | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
| WO2015085172A2 (en) | 2013-12-06 | 2015-06-11 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
| EP4649963A3 (en) * | 2014-04-14 | 2026-05-13 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| TWI745271B (zh) | 2014-05-19 | 2021-11-11 | 美商西建公司 | 全身紅斑性狼瘡之治療 |
| ES2843973T3 (es) | 2014-06-27 | 2021-07-21 | Celgene Corp | Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3 |
| JP6889101B2 (ja) | 2014-08-07 | 2021-06-18 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | グルタミナーゼ阻害剤の結晶形態 |
| AU2015305449B2 (en) | 2014-08-22 | 2021-05-06 | Celgene Corporation | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
| NZ731789A (en) * | 2014-10-30 | 2019-04-26 | Kangpu Biopharmaceuticals Ltd | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| EP3778602B1 (en) * | 2015-07-21 | 2023-07-12 | ImmunoGen, Inc. | Methods of preparing cytotoxic benzodiazepine derivatives |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| CA3000547C (en) * | 2015-09-29 | 2021-03-23 | Kangpu Biopharmaceuticals, Ltd. | Pharmaceutical composition comprising benzoheterocyclic compound and androgen receptor pathway modulator for prevention or treatment of prostate cancer |
| US10830762B2 (en) | 2015-12-28 | 2020-11-10 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
| US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
| EP3440082A1 (en) * | 2016-04-06 | 2019-02-13 | The Regents of The University of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| AU2017250076B2 (en) * | 2016-04-12 | 2021-07-22 | The Regents Of The University Of Michigan | Bet protein degraders |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| SI3526202T1 (sl) | 2016-10-11 | 2025-04-30 | Arvinas Operations, Inc. | Spojine in postopki za ciljno razgradnjo androgenskih receptorjev |
| MX2019004950A (es) | 2016-10-28 | 2019-09-26 | Icahn School Med Mount Sinai | Composiciones y metodos para tratar el cancer mediado por el potenciador del homologo zeste 2. |
| MX2019005007A (es) | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| US11124577B2 (en) | 2016-11-02 | 2021-09-21 | Engmab Sàrl | Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma |
| IL266842B (en) | 2016-12-01 | 2022-09-01 | Arvinas Operations Inc | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists |
| CA3045037A1 (en) | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cdk4/6-mediated cancer |
| KR20220028178A (ko) * | 2016-12-16 | 2022-03-08 | 강푸 바이오파마슈티칼즈 리미티드 | 조성물, 이의 적용 및 치료 방법 |
| CN110753693A (zh) | 2016-12-23 | 2020-02-04 | 阿尔维纳斯运营股份有限公司 | Egfr蛋白水解靶向嵌合分子和相关使用方法 |
| IL325835A (en) | 2016-12-23 | 2026-03-01 | Univ Yale | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| IL300417A (en) | 2017-01-26 | 2023-04-01 | Arvinas Operations Inc | Bifunctional benzothiophene compounds, preparations containing them and their use in therapy |
| JP7062010B2 (ja) * | 2017-01-27 | 2022-05-02 | セルジーン コーポレイション | ３－（１－オキソ－４－（（４－（（３－オキソモルホリノ）メチル）ベンジル）オキシ）イソインドリン－２－イル）ピペリジン－２，６－ジオン及びそのアイソトポログ |
| IL319363A (en) | 2017-01-31 | 2025-05-01 | Arvinas Operations Inc | Cervalon ligands and bifunctional compounds containing them |
| WO2018144832A1 (en) | 2017-02-03 | 2018-08-09 | Celgene Corporation | Methods for measuring small molecule affinity to cereblon |
| JP6773915B2 (ja) | 2017-02-13 | 2020-10-21 | カング バイオファーマシューティカルズ リミテッド | 前立腺癌を治療する組み合わせ、薬物組成物および治療方法 |
| CN108929307A (zh) * | 2017-05-22 | 2018-12-04 | 苏州偶领生物医药有限公司 | 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途 |
| JP7258009B2 (ja) * | 2017-07-10 | 2023-04-14 | セルジーン コーポレイション | 抗増殖化合物及びその使用方法 |
| MX2020002010A (es) | 2017-08-21 | 2020-07-13 | Celgene Corp | Procesos para la preparacion de 4,5-diamino-5-oxopentanoato de (s)-terc-butilo. |
| US10513515B2 (en) * | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
| RU2764243C2 (ru) | 2017-09-22 | 2022-01-14 | ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи | Гетероциклические соединения в качестве ингибиторов PAD |
| CN111225915B (zh) | 2017-10-18 | 2023-03-07 | 朱比兰特埃皮帕德有限公司 | 作为pad抑制剂的咪唑并吡啶化合物 |
| US11629135B2 (en) | 2017-11-06 | 2023-04-18 | Jubilant Prodell Llc | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| RS65576B1 (sr) | 2017-11-24 | 2024-06-28 | Jubilant Episcribe Llc | Heterociklična jedinjenja kao inhibitori prmt5 |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| EP3744719B1 (en) * | 2018-01-25 | 2023-06-07 | Fujimoto Co., Ltd. | Thiophene derivative and use thereof |
| JP2021512153A (ja) | 2018-01-26 | 2021-05-13 | イエール ユニバーシティ | タンパク質分解のイミド系モジュレーターおよび使用方法 |
| BR112020017053A2 (pt) | 2018-02-21 | 2020-12-15 | Celgene Corporation | Anticorpos que se ligam ao bcma e usos dos mesmos |
| JP2021515013A (ja) | 2018-03-06 | 2021-06-17 | アイカーン スクール オブ メディスン アット マウント シナイ | セリンスレオニンキナーゼ（ａｋｔ）分解／破壊化合物および使用方法 |
| CN112105610B (zh) | 2018-03-13 | 2024-01-26 | 朱比连特普罗德尔有限责任公司 | 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物 |
| BR112020020307A2 (pt) | 2018-04-04 | 2021-01-12 | Arvinas Operations, Inc. | Moduladores de proteólise e métodos de uso associados |
| CN118344338A (zh) * | 2018-04-23 | 2024-07-16 | 细胞基因公司 | 取代的4-氨基异吲哚啉-1,3-二酮化合物以及它们用于治疗淋巴瘤的用途 |
| JP2021527666A (ja) | 2018-06-21 | 2021-10-14 | アイカーン スクール オブ メディスン アット マウント シナイ | Ｗｄ４０反復ドメインタンパク質５（ｗｄｒ５）分解／破壊化合物および使用の方法 |
| IL279800B2 (en) | 2018-06-29 | 2024-02-01 | Hoffmann La Roche | Selective allosteric inhibitors of epidermal growth factor receptor mutants, pharmaceutical preparations containing them and their use |
| WO2020010204A1 (en) | 2018-07-05 | 2020-01-09 | Icahn School Of Medicine At Mount Sinai | Protein tyrosine kinase 6 (ptk6) degradation / disruption compounds and methods of use |
| US12454520B2 (en) | 2018-07-06 | 2025-10-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| BR122022012697B1 (pt) * | 2018-07-10 | 2023-04-04 | Novartis Ag | Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit |
| WO2020023782A1 (en) | 2018-07-27 | 2020-01-30 | Biotheryx, Inc. | Bifunctional compounds as cdk modulators |
| US11707452B2 (en) | 2018-08-20 | 2023-07-25 | Arvinas Operations, Inc. | Modulators of alpha-synuclein proteolysis and associated methods of use |
| JP7098825B2 (ja) * | 2018-09-07 | 2022-07-11 | メッドシャイン ディスカバリー インコーポレイテッド | 三環式置換ピペリジンジオン類化合物 |
| CA3121667A1 (en) * | 2018-09-30 | 2020-04-02 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Isoindoline compound, preparation method, pharmaceutical composition and use thereof |
| CA3114401A1 (en) | 2018-10-01 | 2020-04-09 | Celgene Corporation | Combination therapy for the treatment of cancer |
| CN113573719A (zh) | 2018-11-08 | 2021-10-29 | 朱诺治疗学股份有限公司 | 治疗和t细胞调节的方法和组合 |
| AU2019389174A1 (en) | 2018-11-30 | 2021-07-01 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2020118098A1 (en) * | 2018-12-05 | 2020-06-11 | Vividion Therapeutics, Inc. | Substituted isoindolinones as modulators of cereblon-mediated neo-substrate recruitment |
| AU2019392231B2 (en) * | 2018-12-06 | 2022-10-20 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Isoindoline compound, and preparation method, pharmaceutical composition, and application of isoindoline compound |
| AU2020206692B2 (en) | 2019-01-09 | 2025-03-27 | Celgene Corporation | Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same |
| DK3908281T3 (da) | 2019-01-09 | 2024-10-21 | Celgene Corp | Antiproliferative forbindelser og sekundære aktive midler til anvendelse til behandling af multipelt myelom |
| EP3908582B1 (en) * | 2019-01-09 | 2025-11-12 | Celgene Corporation | Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same |
| EP3932922A4 (en) | 2019-02-25 | 2022-05-11 | ShanghaiTech University | SULPHUR-CONTAINING COMPOUND BASED ON A GLUTARIMIDE FRAMEWORK AND ITS USE |
| AR119715A1 (es) | 2019-04-12 | 2022-01-05 | Celgene Corp | Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona |
| CN114423463B (zh) | 2019-05-06 | 2025-09-26 | 西奈山伊坎医学院 | 作为hpk1的降解剂的异双功能化合物 |
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3999182A1 (en) | 2019-07-17 | 2022-05-25 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
| US12558427B2 (en) | 2019-07-17 | 2026-02-24 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| WO2021023233A1 (zh) | 2019-08-05 | 2021-02-11 | 上海科技大学 | Egfr蛋白降解剂及其抗肿瘤应用 |
| WO2021041348A1 (en) | 2019-08-26 | 2021-03-04 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| MX2022004526A (es) | 2019-10-17 | 2022-07-21 | Arvinas Operations Inc | Moléculas bifuncionales que contienen una porción de unión a la ligasa de ubiquitina e3 unida a una porción de direccionamiento a bcl6. |
| IL292375A (en) * | 2019-10-21 | 2022-06-01 | Celgene Corp | Solid forms include (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)metyl)benzyl)amino)isoindoline-1 3- Discussion and salts from them, and preparations that include the same and their use |
| BR112022008522A2 (pt) | 2019-11-05 | 2022-07-26 | Celgene Corp | Usos de receptores de antígeno quimérico anti-bcma |
| EP4054623A1 (en) | 2019-11-07 | 2022-09-14 | Juno Therapeutics, Inc. | Combination of a t cell therapy and (s)-3-[4-(4-morpholin-4 ylmethyl-benzyloxy)-l-oxo-l,3-dihydro-isoindol-2-yl]- piperidine-2,6-dione |
| WO2021105335A1 (en) | 2019-11-27 | 2021-06-03 | Captor Therapeutics S.A. | Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof |
| JP7852923B2 (ja) | 2019-11-27 | 2026-04-28 | キャプター セラピューティクス エス．エー． | セレブロンに結合するピペリジン－２，６－ジオン誘導体、及びその使用方法 |
| KR20220110243A (ko) | 2019-12-02 | 2022-08-05 | 셀진 코포레이션 | 암의 치료를 위한 요법 |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CN115003295B (zh) | 2019-12-12 | 2025-05-06 | 冰洲石生物科技公司 | 具有雌激素受体降解活性的新型色满衍生物及其用途 |
| CA3161878A1 (en) | 2019-12-17 | 2021-06-24 | Matthew M. Weiss | Irak degraders and uses thereof |
| PH12022551482A1 (en) | 2019-12-18 | 2023-11-29 | Novartis Ag | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| WO2021127443A1 (en) | 2019-12-19 | 2021-06-24 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CN116234803B (zh) | 2019-12-23 | 2026-06-30 | 冰洲石生物科技公司 | 用于治疗癌症的雌激素受体降解剂和细胞周期蛋白依赖性激酶抑制剂的组合 |
| EP4095132A1 (en) * | 2020-01-20 | 2022-11-30 | Kangpu Biopharmaceuticals, Ltd. | Isoindoline derivative, and pharmaceutical composition and use thereof |
| AU2021226514B2 (en) * | 2020-02-25 | 2023-10-19 | Shanghaitech University | Glutarimide skeleton-based compounds and application thereof |
| EP4143329A4 (en) | 2020-04-28 | 2024-10-16 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
| AU2021263408A1 (en) | 2020-04-30 | 2022-10-27 | Bristol-Myers Squibb Company | Methods of treating cytokine-related adverse events |
| CN115996918A (zh) | 2020-05-09 | 2023-04-21 | 阿尔维纳斯运营股份有限公司 | 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型 |
| US12103924B2 (en) | 2020-06-01 | 2024-10-01 | Icahn School Of Medicine At Mount Sinai | Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use |
| EP4161521A4 (en) | 2020-06-03 | 2024-07-10 | Kymera Therapeutics, Inc. | DEUTERED IRAQ DEGRADERS AND USES THEREOF |
| CN115916191B (zh) | 2020-06-25 | 2026-06-23 | 新基公司 | 用组合疗法治疗癌症的方法 |
| CN113896711A (zh) * | 2020-07-06 | 2022-01-07 | 北京诺诚健华医药科技有限公司 | 杂环类免疫调节剂 |
| CN120004860A (zh) * | 2020-07-20 | 2025-05-16 | 江苏恒瑞医药股份有限公司 | 含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用 |
| AU2021319847A1 (en) | 2020-08-03 | 2023-03-02 | Captor Therapeutics S.A. | Low molecular weight protein degraders and their applications |
| WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| US20230310478A1 (en) * | 2020-09-02 | 2023-10-05 | Ann And Robert H. Lurie Children's Hospital Of Chicago | Methods and compositions for the treatment of pulmonary hypertension and cancer |
| CA3191282A1 (en) | 2020-09-11 | 2022-03-17 | William Pierceall | Combination therapy for cancer |
| AU2021342287A1 (en) | 2020-09-14 | 2023-04-13 | Arvinas Operations, Inc. | Crystalline forms of a compound for the targeted degradation of estrogen receptor |
| WO2022066580A1 (en) * | 2020-09-23 | 2022-03-31 | Kinnate Biopharma Inc. | Raf degrading compounds |
| JP2023544351A (ja) * | 2020-10-02 | 2023-10-23 | セルジーン コーポレーション | 全身性エリテマトーデスを治療する方法及び治療に対する臨床的感受性の予測因子としてのバイオマーカの使用 |
| US20230398149A1 (en) | 2020-11-04 | 2023-12-14 | Celgene Corporation | Car t cell therapy in patients who have had prior anti-cancer alkylator therapy |
| CN112174976A (zh) * | 2020-11-19 | 2021-01-05 | 江西中医药大学 | 从水芹菜中分离的二苯并呋喃型木脂素及其方法和在抗痛风性关节炎上的用途 |
| AR124547A1 (es) | 2020-12-30 | 2023-04-05 | Kymera Therapeutics Inc | Degradadores de irak y sus usos |
| WO2022146151A1 (en) | 2020-12-30 | 2022-07-07 | Captor Therapeutics S.A. | Novel compounds which bind to cereblon, and methods of use thereof |
| WO2022148358A1 (zh) * | 2021-01-05 | 2022-07-14 | 江苏恒瑞医药股份有限公司 | 稠杂环基取代的环己二酰亚胺衍生物、其制备方法及其在医药上的应用 |
| CN117242060B (zh) | 2021-01-13 | 2026-07-17 | 蒙特罗莎治疗股份有限公司 | 异吲哚啉酮化合物 |
| MX2023009178A (es) | 2021-02-15 | 2023-08-21 | Kymera Therapeutics Inc | Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos. |
| WO2022174268A1 (en) | 2021-02-15 | 2022-08-18 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| UY39671A (es) * | 2021-03-15 | 2022-10-31 | Novartis Ag | Derivados de pirazolopiridina y sus usos. |
| MX2023011378A (es) * | 2021-03-31 | 2023-10-06 | Duke Street Bio Ltd | Compuesto farmaceutico. |
| CN118388454A (zh) | 2021-04-16 | 2024-07-26 | 阿尔维纳斯运营股份有限公司 | Bcl6蛋白水解的调节剂和其相关使用方法 |
| WO2022255890A1 (en) | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Compounds which bind to cereblon, and use thereof |
| WO2022255889A1 (en) | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Compounds which bind to cereblon, and use thereof |
| WO2022254362A1 (en) | 2021-06-03 | 2022-12-08 | Novartis Ag | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof |
| CN115504963A (zh) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
| WO2023025136A1 (zh) * | 2021-08-27 | 2023-03-02 | 杭州格博生物医药有限公司 | 异吲哚啉酮化合物及其用途 |
| EP4395549A1 (en) * | 2021-09-01 | 2024-07-10 | Oerth Bio LLC | Compositions and methods for targeted degradation of proteins in a plant cell |
| JP2024540080A (ja) | 2021-10-29 | 2024-10-31 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ４分解剤およびその合成 |
| CN116462660A (zh) * | 2022-01-19 | 2023-07-21 | 江苏恒瑞医药股份有限公司 | 一种异喹啉酮类化合物的盐及其晶型 |
| MX2024008959A (es) * | 2022-01-19 | 2024-07-30 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Forma cristalina de derivado de isoindolina que contiene azufre. |
| EP4472967A4 (en) | 2022-01-31 | 2026-04-15 | Kymera Therapeutics Inc | Iraqi Degradation Agents and Their Uses |
| US20250295771A1 (en) | 2022-05-11 | 2025-09-25 | Celgene Corporation | Methods and uses related to t cell therapy and production of same |
| US20250302954A1 (en) | 2022-05-11 | 2025-10-02 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| CN115160211B (zh) * | 2022-06-23 | 2023-11-03 | 温州大学 | 一种异吲哚啉酮类化合物的绿色合成方法 |
| US20250270202A1 (en) * | 2022-06-24 | 2025-08-28 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Substituted 4-aminoisoindoline compound, preparation method therefor, pharmaceutical composition thereof, and use thereof |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| US20260098035A1 (en) | 2022-09-20 | 2026-04-09 | Celgene Corporation | Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same |
| US20260166082A1 (en) | 2022-11-02 | 2026-06-18 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
| EP4619399A1 (en) | 2022-11-16 | 2025-09-24 | Basf Se | New substituted tetrahydrobenzoxazepine |
| EP4644382A4 (en) * | 2022-12-27 | 2026-04-01 | Gluetacs Therapeutics Shanghai Co Ltd | ISOINDOLINONE SKELETON-BASED COMPOUND WITH SULFUR/OXYGEN SUBSTITUTED GLUTARIMIDE AND ITS USE |
| PE20260006A1 (es) | 2023-01-26 | 2026-01-06 | Arvinas Operations Inc | Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos |
| WO2024167423A1 (en) | 2023-02-07 | 2024-08-15 | Captor Therapeutics S.A. | Gspt1 degrader compounds |
| KR20260057078A (ko) | 2023-08-18 | 2026-04-27 | 브리스톨-마이어스 스큅 컴퍼니 | Bcma 및 cd3에 결합하는 항체를 포함하는 조성물 및 치료 방법 |
| KR20260088542A (ko) | 2023-10-06 | 2026-06-12 | 주노 쎄러퓨티크스 인코퍼레이티드 | Gprc5d-표적화 car을 발현하는 세포 요법을 사용한 조합 요법 및 관련 방법 및 용도 |
| AU2024392985A1 (en) | 2023-12-08 | 2026-06-04 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
| TW202532072A (zh) | 2023-12-08 | 2025-08-16 | 美商西建公司 | 治療多發性骨髓瘤之療法 |
| WO2025195464A1 (zh) * | 2024-03-21 | 2025-09-25 | 上海惠康济民生物医药技术有限公司 | 取代的异吲哚啉类化合物、制备方法、药物组合物及应用 |
| TW202619716A (zh) | 2024-07-23 | 2026-05-16 | 法商賽諾菲公司 | Ｃｅｒｅｂｌｏｎ連接酶調節劑與ｂｃｍａ ｎｋ細胞銜接子的組合療法 |
| WO2026035999A1 (en) | 2024-08-09 | 2026-02-12 | Triana Biomedicines, Inc. | Anaplastic lymphoma kinase (alk) degraders and uses thereof |
| WO2026149422A1 (zh) * | 2025-01-08 | 2026-07-16 | 上海惠康济民生物医药技术有限公司 | 含吗啉基的异吲哚啉化合物的晶型及其制备方法和应用 |
Family Cites Families (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4421865A (en) * | 1981-06-08 | 1983-12-20 | Standard Oil Company (Sohio) | Selective hydrogen-deuterium interchange using ion exchange resins |
| US4994443A (en) | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| US5001116A (en) | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| KR890002631B1 (ko) | 1984-10-04 | 1989-07-21 | 몬산토 캄파니 | 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물 |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5149820A (en) * | 1987-03-11 | 1992-09-22 | Norsk Hydro A.S. | Deuterated compounds |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| AU1531492A (en) * | 1991-02-14 | 1992-09-15 | Rockefeller University, The | Method for controlling abnormal concentration tnf alpha in human tissues |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| CA2146126A1 (en) * | 1992-10-07 | 1994-04-14 | Sumitomo Pharmaceuticals Company, Limited | Pharmaceutical compositions for inhibiting the formation of tumor necrosis factor |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| WO1995003807A1 (en) | 1993-07-27 | 1995-02-09 | The University Of Sydney | Treatment of age-related macular degeneration |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| IT1274549B (it) | 1995-05-23 | 1997-07-17 | Indena Spa | Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno |
| DE69632684T2 (de) | 1995-06-27 | 2005-06-09 | Takeda Pharmaceutical Co. Ltd. | Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US5800819A (en) | 1996-01-25 | 1998-09-01 | National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology | Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| DE69740140D1 (de) | 1996-07-24 | 2011-04-14 | Celgene Corp | Substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide und Oxoisoindoline und Verfahren zur Verringerung der TNF-Alpha-Stufen |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| ES2221019T3 (es) | 1996-10-31 | 2004-12-16 | Takeda Chemical Industries, Ltd. | Preparacion de liberacion mantenida. |
| EP0946169B1 (en) | 1996-12-20 | 2003-02-26 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| TR200101500T2 (tr) | 1998-03-16 | 2002-06-21 | Celgene Corporation | 2-(2,6-dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuarn sitokinlerin inhibitörleri olarak kullanımı. |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| US6015803A (en) | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US6225348B1 (en) | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
| US6001368A (en) | 1998-09-03 | 1999-12-14 | Protein Technologies International, Inc. | Method for inhibiting or reducing the risk of macular degeneration |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
| DE60117486T2 (de) | 2000-08-23 | 2006-11-16 | General Electric Co. | Spritzgegossene Keramik-Metallhalogenidbogenröhre mit einem nicht-konischen Ende |
| US6458810B1 (en) * | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| US20040190609A1 (en) | 2001-11-09 | 2004-09-30 | Yasuhiko Watanabe | Moving picture coding method and apparatus |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| DK1505973T3 (da) | 2002-05-17 | 2010-05-31 | Celgene Corp | Kombinationer til behandling af multipelt myelom |
| US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| CA2808646C (en) | 2003-09-17 | 2016-08-23 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Thalidomide analogs as tnf-alpha modulators |
| US20050100529A1 (en) | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| BRPI0417186A (pt) | 2003-12-02 | 2007-03-06 | Celgene Corp | método de tratamento de um indivìduo tendo uma hemoglobinopatia ou uma anemia, de modulação da diferenciação de uma célula-tronco ou precursora de cd34+ para uma linhagem de eritróides, e, composição farmacêutica |
| US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
| AU2005226649B2 (en) | 2004-03-22 | 2010-04-29 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders |
| US20050222209A1 (en) | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
| BRPI0510110A (pt) | 2004-04-23 | 2007-09-25 | Celgene Corp | método para tratar, prevenir ou controlar hipertensão pulmonar, e, composição farmacêutica |
| WO2005112928A1 (en) | 2004-05-05 | 2005-12-01 | Celgene Corporation | Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases |
| DE602005023172D1 (de) * | 2004-07-16 | 2010-10-07 | Schering Corp | Hydantoinderivate zur behandlung von entzündlichen erkrankungen |
| US7244759B2 (en) | 2004-07-28 | 2007-07-17 | Celgene Corporation | Isoindoline compounds and methods of making and using the same |
| US7405237B2 (en) | 2004-07-28 | 2008-07-29 | Celgene Corporation | Isoindoline compounds and methods of their use |
| NZ554068A (en) * | 2004-09-03 | 2009-07-31 | Celgene Corp | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindo-lines |
| WO2006053160A2 (en) | 2004-11-12 | 2006-05-18 | Celgene Corporation | Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases |
| CN101102771A (zh) | 2004-11-23 | 2008-01-09 | 细胞基因公司 | 用免疫调节化合物治疗和控制中枢神经系统损伤的方法和组合物 |
| AU2005311888A1 (en) | 2004-12-01 | 2006-06-08 | Celgene Corporation | Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders |
| PL1907373T3 (pl) | 2005-06-30 | 2013-05-31 | Celgene Corp | Sposób wytwarzania związków 4-amino-2-(2,6-diokso-piperydyn-3-ylo)izoindolino-1,3-dionu |
| CA2822094C (en) * | 2005-08-31 | 2015-10-27 | Celgene Corporation | Isoindole-imide compounds and compositions comprising and methods of using the same |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| US8648096B2 (en) | 2006-09-15 | 2014-02-11 | Celgene Corporation | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same |
| US20110184025A1 (en) | 2006-10-19 | 2011-07-28 | Hensel Jennifer L | Methods and Compositions Using Immunomodulatory Compounds for the Treatment and Management of Spirochete and Other Obligate Intracellular Bacterial Diseases |
| CA2681633C (en) * | 2007-03-20 | 2018-01-09 | Celgene Corporation | 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same |
| SG183257A1 (en) * | 2010-02-11 | 2012-09-27 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| WO2012027065A2 (en) | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
| WO2012068512A1 (en) | 2010-11-18 | 2012-05-24 | Deuteria Pharmaceuticals Llc | 3-deutero-pomalidomide |
| WO2012079022A1 (en) | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| EP2699091B1 (en) | 2011-03-28 | 2017-06-21 | DeuteRx, LLC | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| ES2872967T3 (es) | 2012-06-29 | 2021-11-03 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS) |
| KR20210073616A (ko) | 2012-08-09 | 2021-06-18 | 셀진 코포레이션 | 면역-관련 및 염증성 질환의 치료 |
| HK1211577A1 (en) | 2012-08-09 | 2016-05-27 | 细胞基因公司 | Processes for the preparation of (s)-3-4- ((4-(morpholinomethyl) benzyl)oxy)-1-oxoisoindolin-2-yl) piperidine-2,6-dione and pharmaceutically acceptable forms thereof |
| US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
| US20140343058A1 (en) | 2012-08-09 | 2014-11-20 | Celgene Corporation | Treatment of systemic lupus erythematosus |
| UA116544C2 (uk) | 2012-08-09 | 2018-04-10 | Селджин Корпорейшн | Спосіб лікування раку з використанням 3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
| LT2882737T (lt) | 2012-08-09 | 2019-04-25 | Celgene Corporation | (s)-3-(4-((4-morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-diono hidrochlorido kieta forma |
| US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
| CN104797256A (zh) | 2012-09-10 | 2015-07-22 | 细胞基因公司 | 用于治疗局部晚期乳腺癌的方法 |
| US9695145B2 (en) | 2013-01-22 | 2017-07-04 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| US9872854B2 (en) | 2013-03-14 | 2018-01-23 | Celgene Corporation | Methods for the treatment of psoriatic arthritis using apremilast |
| CA2908954C (en) | 2013-04-17 | 2021-08-03 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer |
| UA117141C2 (uk) | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
| WO2015085172A2 (en) | 2013-12-06 | 2015-06-11 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
| US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| TWI745271B (zh) | 2014-05-19 | 2021-11-11 | 美商西建公司 | 全身紅斑性狼瘡之治療 |
| ES2843973T3 (es) | 2014-06-27 | 2021-07-21 | Celgene Corp | Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3 |
| WO2016025686A1 (en) | 2014-08-15 | 2016-02-18 | Celgene Corporation | Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition |
| JP2017533727A (ja) | 2014-10-13 | 2017-11-16 | セルジーン コーポレイション | 固形腫瘍の治療方法及び免疫調節療法への臨床的感度の予測因子としてのバイオマーカーの使用 |
| NZ731789A (en) | 2014-10-30 | 2019-04-26 | Kangpu Biopharmaceuticals Ltd | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof |
| US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
-
2011
- 2011-02-10 SG SG2012059259A patent/SG183257A1/en unknown
- 2011-02-10 EP EP11704156.6A patent/EP2536706B1/en active Active
- 2011-02-10 CA CA2787823A patent/CA2787823C/en active Active
- 2011-02-10 MX MX2012009237A patent/MX2012009237A/es active IP Right Grant
- 2011-02-10 HU HUE11704156A patent/HUE033009T2/en unknown
- 2011-02-10 NZ NZ700054A patent/NZ700054A/en unknown
- 2011-02-10 ES ES11704156.6T patent/ES2638517T3/es active Active
- 2011-02-10 SM SM20170360T patent/SMT201700360T1/it unknown
- 2011-02-10 MX MX2016001880A patent/MX367522B/es unknown
- 2011-02-10 SM SM20190420T patent/SMT201900420T1/it unknown
- 2011-02-10 CN CN201510039358.XA patent/CN104693193B/zh active Active
- 2011-02-10 PT PT17157170T patent/PT3202460T/pt unknown
- 2011-02-10 TR TR2019/03027T patent/TR201903027T4/tr unknown
- 2011-02-10 US US13/025,105 patent/US8518972B2/en active Active
- 2011-02-10 SI SI201131754T patent/SI3202460T1/sl unknown
- 2011-02-10 EP EP17157178.9A patent/EP3202461B1/en active Active
- 2011-02-10 HU HUE17157178A patent/HUE042011T2/hu unknown
- 2011-02-10 LT LTEP17157170.6T patent/LT3202460T/lt unknown
- 2011-02-10 PL PL17157170T patent/PL3202460T3/pl unknown
- 2011-02-10 LT LTEP11704156.6T patent/LT2536706T/lt unknown
- 2011-02-10 RU RU2012138709/04A patent/RU2567753C2/ru active
- 2011-02-10 MX MX2013011071A patent/MX337169B/es unknown
- 2011-02-10 EP EP23192393.9A patent/EP4289838A3/en active Pending
- 2011-02-10 ME MEP-2019-195A patent/ME03441B/me unknown
- 2011-02-10 SG SG10202012179RA patent/SG10202012179RA/en unknown
- 2011-02-10 PL PL17157178T patent/PL3202461T3/pl unknown
- 2011-02-10 HR HRP20171078TT patent/HRP20171078T1/hr unknown
- 2011-02-10 ES ES19178064T patent/ES2956743T3/es active Active
- 2011-02-10 PT PT117041566T patent/PT2536706T/pt unknown
- 2011-02-10 CN CN201180018485.1A patent/CN102822165B/zh active Active
- 2011-02-10 EP EP17157170.6A patent/EP3202460B1/en active Active
- 2011-02-10 EP EP19178064.2A patent/EP3599236B1/en active Active
- 2011-02-10 RS RSP20190965 patent/RS59275B1/sr unknown
- 2011-02-10 DK DK17157178.9T patent/DK3202461T3/en active
- 2011-02-10 SM SM20190155T patent/SMT201900155T1/it unknown
- 2011-02-10 SI SI201131241T patent/SI2536706T1/sl unknown
- 2011-02-10 UA UAA201601384A patent/UA114856C2/uk unknown
- 2011-02-10 UA UAA201210643A patent/UA115220C2/uk unknown
- 2011-02-10 PL PL11704156T patent/PL2536706T3/pl unknown
- 2011-02-10 HU HUE17157170 patent/HUE044652T2/hu unknown
- 2011-02-10 ES ES17157178T patent/ES2713482T3/es active Active
- 2011-02-10 PT PT17157178T patent/PT3202461T/pt unknown
- 2011-02-10 NZ NZ601289A patent/NZ601289A/en unknown
- 2011-02-10 ME MEP-2017-136A patent/ME02766B/me unknown
- 2011-02-10 KR KR1020127023615A patent/KR101812356B1/ko active Active
- 2011-02-10 SI SI201131680T patent/SI3202461T1/sl unknown
- 2011-02-10 WO PCT/US2011/024269 patent/WO2011100380A1/en not_active Ceased
- 2011-02-10 PH PH1/2012/501607A patent/PH12012501607A1/en unknown
- 2011-02-10 LT LTEP17157178.9T patent/LT3202461T/lt unknown
- 2011-02-10 ES ES17157170T patent/ES2738776T3/es active Active
- 2011-02-10 RS RS20170700A patent/RS56232B1/sr unknown
- 2011-02-10 NZ NZ717149A patent/NZ717149A/en unknown
- 2011-02-10 AU AU2011215877A patent/AU2011215877C1/en active Active
- 2011-02-10 DK DK17157170.6T patent/DK3202460T3/da active
- 2011-02-10 EP EP16166423.0A patent/EP3106460B1/en active Active
- 2011-02-10 DK DK11704156.6T patent/DK2536706T3/en active
- 2011-02-10 ES ES16166423T patent/ES2730763T3/es active Active
- 2011-02-10 SG SG10201501062SA patent/SG10201501062SA/en unknown
- 2011-02-10 RS RS20190249A patent/RS58523B1/sr unknown
- 2011-02-10 JP JP2012552978A patent/JP2013519675A/ja not_active Withdrawn
- 2011-02-10 KR KR1020177036343A patent/KR101931468B1/ko active Active
- 2011-02-11 AR ARP110100436A patent/AR081058A1/es active IP Right Grant
-
2012
- 2012-07-17 IL IL220992A patent/IL220992A/en active IP Right Grant
- 2012-08-09 NI NI201200132A patent/NI201200132A/es unknown
- 2012-08-09 CR CR20120414A patent/CR20120414A/es unknown
- 2012-08-09 EC ECSP12012098 patent/ECSP12012098A/es unknown
- 2012-08-10 CO CO12135141A patent/CO6571916A2/es active IP Right Grant
-
2013
- 2013-07-26 US US13/952,386 patent/US9309219B2/en active Active
-
2014
- 2014-05-14 PH PH12014501082A patent/PH12014501082B1/en unknown
-
2016
- 2016-01-14 JP JP2016004951A patent/JP6215976B2/ja active Active
- 2016-02-10 US US15/040,980 patent/US9822094B2/en active Active
- 2016-02-10 US US15/040,971 patent/US9828361B2/en active Active
- 2016-04-13 JP JP2016080097A patent/JP2016172746A/ja not_active Withdrawn
- 2016-09-02 JP JP2016171451A patent/JP6270944B2/ja active Active
- 2016-11-08 IL IL248843A patent/IL248843B/en active IP Right Grant
-
2017
- 2017-06-27 JP JP2017125219A patent/JP2017200944A/ja active Pending
- 2017-07-18 CY CY20171100759T patent/CY1119177T1/el unknown
- 2017-10-17 US US15/786,334 patent/US10189814B2/en active Active
-
2018
- 2018-11-19 US US16/195,550 patent/US10669257B2/en active Active
-
2019
- 2019-02-22 CY CY20191100227T patent/CY1121729T1/el unknown
- 2019-02-26 HR HRP20190368TT patent/HRP20190368T1/hr unknown
- 2019-07-19 HR HRP20191312TT patent/HRP20191312T1/hr unknown
- 2019-08-02 CY CY20191100823T patent/CY1121858T1/el unknown
-
2020
- 2020-03-31 US US16/836,832 patent/US11414399B2/en active Active
-
2022
- 2022-07-18 US US17/867,294 patent/US20220411402A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010504973A5 (enExample) | ||
| JP2009506117A5 (enExample) | ||
| CY1120049T1 (el) | (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| JP2014511891A5 (enExample) | ||
| JP2018021046A5 (enExample) | ||
| JP2016518337A5 (enExample) | ||
| JP2010502627A5 (enExample) | ||
| EP4663636A3 (en) | Trifluoromethyl substituted pyrazoles as human plasma kallikrein inhibitors | |
| JP2015110588A5 (enExample) | ||
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| ME02910B (me) | Spojevi tetrahidropirolotiazina | |
| JP2014511892A5 (enExample) | ||
| EA201401150A1 (ru) | Аминоиндолилзамещенные имидазолпиримидины и их применение в качестве лекарственных средств | |
| JP2016510326A5 (enExample) | ||
| ME02841B (me) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| JP2016523260A5 (enExample) | ||
| JP2016522254A5 (enExample) | ||
| AR100663A1 (es) | Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona | |
| JP2015516419A5 (enExample) | ||
| MA37455A1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
| JP2016537338A5 (enExample) | ||
| EA201692298A1 (ru) | Производные карбоксамидов | |
| JP2013515073A5 (enExample) | ||
| JP2017513944A5 (enExample) |